Feline Chronic Gingivostomatitis (FCGS), also known as Lymphocytic Plasmacytic Stomatitis (LPS), is a severe, chronic, immune-mediated inflammatory disease of the oral cavity affecting domestic cats.
Overview and Clinical Importance
Feline Chronic Gingivostomatitis (FCGS), also known as Lymphocytic Plasmacytic Stomatitis (LPS), is a severe, chronic, immune-mediated inflammatory disease of the oral cavity affecting domestic cats. This debilitating condition is characterized by profound inflammation extending beyond the gingiva to involve the buccal mucosa, palatoglossal folds, and caudal oral cavity. FCGS represents one of the most challenging oral diseases in feline medicine due to its unclear etiology, chronic course, and variable response to treatment.
The prevalence of FCGS ranges from 0.7% to 12% of the domestic cat population, with the disease more commonly affecting cats in multicat households. The median age of affected cats is approximately 7 years, though cats as young as 4 months can be affected. This condition significantly impacts quality of life due to severe oral pain, often leading to anorexia, weight loss, and behavioral changes.
High-YieldFCGS is one of the most commonly tested oral diseases on the NAVLE. Remember the hallmark finding: inflammation extending BEYOND the mucogingival junction to the caudal oral cavity, particularly the palatoglossal folds (fauces). This distinguishes it from simple gingivitis.
| Factor Category |
Details and Clinical Significance |
| Feline Calicivirus (FCV) |
Most consistently associated pathogen; detected in 60% of FCGS cats versus 24% of controls
Chronic carriers show antigenic drift, evading immune clearance
FCV load may decrease with resolution of clinical signs |
| FIV/FeLV |
FeLV-positive cats have 7.5x greater chance of NO improvement after extraction
Associated with immunosuppression that may potentiate disease
Testing recommended but not causally proven |
| Bacterial Dysbiosis |
Higher alpha diversity in subgingival microbiome of FCGS cats
Increased Peptostreptococcus and gram-negative anaerobes
Dental plaque acts as chronic antigenic stimulus |
| Immune Dysregulation |
Decreased CD4/CD8 ratio with increased cytotoxic CD8+ T cells
Elevated circulating IFN-gamma, TNF-alpha, and IL-1beta
Hyperglobulinemia present in 60% of patients |
| Environmental Factors |
Multicat households: each additional cat increases odds by greater than 70%
Stress and chronic viral exposure in group housing
No proven association with outdoor access |
Etiology and Pathophysiology
The exact etiology of FCGS remains multifactorial and incompletely understood. Current evidence suggests the disease results from an inappropriate immune response to chronic antigenic stimulation, likely involving both infectious and host factors.
Proposed Contributing Factors
NAVLE TipThe NAVLE frequently tests the immune-mediated nature of FCGS. Remember: CD8+ cytotoxic T cells predominate locally and systemically, and the CD4/CD8 ratio is decreased. This aberrant immune response to chronic antigenic stimulation (plaque, viruses) is the key pathophysiologic mechanism.
F - FCV (Feline Calicivirus) most commonly associated
L - Lymphocytic/Plasmacytic infiltrate on histopathology
A - Area lateral to palatoglossal folds (caudal stomatitis)
M - Multicat households increase risk
E - Extraction of teeth is gold standard treatment
S - Seven years median age of onset
| Oral Signs |
Behavioral Signs |
Systemic Signs |
| Severe halitosis
Ptyalism (drooling)
Blood-tinged saliva
Erythematous, proliferative, or ulcerative lesions
Bilateral caudal stomatitis |
Dysphagia
Pawing at mouth
Reluctance to eat
Head shaking
Crying when yawning
Decreased grooming |
Weight loss
Poor body condition
Dehydration
Lymphadenopathy (mandibular)
Unkempt hair coat
Social withdrawal |
Clinical Presentation
Clinical Signs
Cats with FCGS typically present with signs reflecting severe oral pain and systemic effects of chronic inflammation:
Disease Classification
FCGS can be classified into two types based on clinical presentation:
Phenotypic Presentation
Lesions may present as ulcerative, proliferative, or ulceroproliferative. The proliferative form can be so severe as to prevent normal tongue retraction. Concurrent conditions commonly observed include periodontal disease, tooth resorption, and retained roots.
High-YieldThe KEY distinguishing feature of FCGS versus simple gingivitis: inflammation extends BEYOND the mucogingival junction to involve the buccal mucosa and caudal oral cavity (palatoglossal folds). Simple gingivitis is confined to the gingival tissue only.
| Type |
Characteristics |
Prognosis |
| Type 1 |
Alveolar, labial/buccal mucositis/stomatitis; inflammation primarily around teeth |
Better prognosis; more likely to respond to extraction |
| Type 2 |
Caudal stomatitis with or without alveolar/buccal involvement; inflammation at palatoglossal folds (85% of cases) |
More guarded prognosis; may be refractory to treatment |
Diagnostic Approach
Recommended Diagnostic Workup
Stomatitis Disease Activity Index (SDAI)
The SDAI is a standardized scoring system used to monitor disease severity and treatment response. It combines owner assessment of quality of life (appetite, activity, grooming, comfort) with veterinary evaluation of oral lesions (0-3 scale for ulceration, erythema, proliferation across seven oral areas). Scores range from 0 (no disease) to 30 (severe disease).
NAVLE TipHistopathology is essential to confirm diagnosis and rule out oral squamous cell carcinoma (SCC), which can mimic FCGS. The hallmark histologic finding is lymphocytic-plasmacytic infiltration with CD3+ T cells in the epithelium and CD20+ B cells in the submucosa. Mott cells (plasma cells with Russell bodies) are characteristic.
| Diagnostic Test |
Purpose |
Expected Findings in FCGS |
| Complete Oral Exam (under anesthesia) |
Assess extent and location of lesions |
Bilateral caudal stomatitis; ulcerative/proliferative lesions extending past mucogingival junction |
| Full-Mouth Dental Radiographs |
Evaluate periodontal disease, tooth resorption, retained roots |
Generalized periodontitis; horizontal alveolar bone loss; external inflammatory root resorption |
| Incisional Biopsy with Histopathology |
Confirm diagnosis; rule out neoplasia (SCC) |
Lymphocytic-plasmacytic infiltrate with fewer neutrophils, mast cells, and Mott cells |
| CBC/Chemistry/Urinalysis |
Assess systemic health; rule out metabolic disease |
Hyperglobulinemia (60%); neutrophilia (30-40%); may see anemia of chronic disease |
| FIV/FeLV Testing |
Assess retroviral status for prognosis |
FeLV+ cats have worse prognosis; 7.5x more likely to fail extraction therapy |
| T4 (Thyroid Panel) |
Rule out hyperthyroidism as contributing factor |
Should be within normal limits unless concurrent disease |
Treatment Options
Treatment of FCGS requires a multimodal approach combining surgical intervention (gold standard) with medical management and appropriate analgesia. Pain management is paramount throughout treatment.
Surgical Treatment: Dental Extractions
Dental extraction is the gold standard treatment, with the goal of removing the chronic antigenic stimulus (dental plaque). Two approaches are used:
Expected Surgical Outcomes
- 28-52% achieve complete clinical cure
- 39% achieve substantial improvement
- 26% show minimal improvement (require ongoing medical management)
- 6-10% are completely refractory
Overall, 70-80% of cats show substantial improvement or cure with dental extractions.
High-YieldCRITICAL surgical principle: Complete removal of ALL tooth structure including roots is essential. Retained root tips perpetuate inflammation and treatment failure. Post-operative dental radiographs MUST confirm complete extraction.
Medical Management
NAVLE TipCyclosporine is the FIRST-CHOICE immunomodulator for refractory FCGS post-extraction. Target trough whole blood levels greater than 300 ng/mL for optimal response (72% improvement at this level). Test trough levels monthly if no clinical improvement. Remember: cyclosporine targets T-cells, which are central to FCGS pathophysiology!
| Extraction Type |
Description |
Expected Outcomes |
| Partial-Mouth Extraction (PME) |
All premolars and molars extracted; canines and incisors may be retained if healthy |
Recommended as FIRST-LINE; reduces anesthetic time; success similar to FME |
| Full-Mouth Extraction (FME) |
All teeth extracted including canines and incisors |
Reserved for cases not responding to PME within 1-4 months; more invasive |
Prognosis and Monitoring
Prognostic Factors
Post-Treatment Monitoring
- 2-4 weeks post-op: Evaluate healing; sutures should exfoliate by this time
- 4-6 weeks post-op: First assessment of treatment response after suture resorption
- 1-4 months post-op: If no improvement after PME, consider FME
- Ongoing: SDAI scoring at each visit; monitor for esophagitis (concurrent in 98% of cases)
High-YieldCats with refractory FCGS may have concurrent ESOPHAGITIS (found in 98% of FCGS cases on endoscopy). Consider empirical treatment for esophagitis in cats not responding to standard therapy.
| Drug/Therapy |
Dosage |
Mechanism |
Efficacy/Notes |
| Prednisolone |
1-2 mg/kg PO q24h tapering |
Immunosuppressive; anti-inflammatory |
Short-term use only; 23% show improvement; long-term side effects limit use |
| Cyclosporine (Atopica) |
2.5-7.5 mg/kg PO q12-24h; target trough greater than 300 ng/mL |
Calcineurin inhibitor; blocks T-cell activation |
45-77% improvement; first-choice for refractory cases post-extraction |
| rFeIFN-omega |
Oromucosal or SC; species-specific dosing |
Antiviral; immunomodulatory |
45-55% improvement; US availability limited (FDA Compassionate Use) |
| Mesenchymal Stem Cells |
2 x 10^7 cells IV; 2-4 doses |
Immunomodulatory; normalizes CD4/CD8 ratio |
60-70% improvement in refractory cases; emerging therapy |
| Buprenorphine |
0.01-0.03 mg/kg buccal/SQ q6-12h |
Partial mu-opioid agonist |
ESSENTIAL for pain management; buccal absorption effective even with oral disease |
| Gabapentin |
5-10 mg/kg PO q8-12h |
GABA analog; neuropathic pain |
Adjunct analgesic; may cause sedation |
| Favorable Prognosis |
Guarded/Poor Prognosis |
| Type 1 FCGS (alveolar predominant)
FIV/FeLV negative
Complete tooth extraction with radiographic confirmation
Shorter disease duration prior to treatment
Single-cat household |
Type 2 FCGS (caudal predominant)
FeLV positive (7.5x worse response)
Retained root fragments
Chronic disease with multiple failed treatments
Multicat household with ongoing exposure |